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ABSTRACT
Gene therapy has long been regarded as a promising treatment for cancer. 
However, cancer gene therapy is still facing the challenge of targeting gene delivery 
vectors specifically to tumors when administered via clinically acceptable non-
invasive systemic routes (i.e. intravenous). The bacteria virus, bacteriophage (phage), 
represents a new generation of promising vectors in systemic gene delivery since 
their targeting can be achieved through phage capsid display ligands, which enable 
them to home to specific tumor receptors without the need to ablate any native 
eukaryotic tropism. We have previously reported a tumor specific bacteriophage vector 
named adeno-associated virus/phage, or AAVP, in which gene expression is under 
a recombinant human rAAV2 virus genome targeted to tumors via a ligand-directed 
phage capsid. However, cancer gene therapy with this tumor-targeted vector achieved 
variable outcomes ranging from tumor regression to no effect in both experimental 
and natural preclinical models. Herein, we hypothesized that combining the natural 
dietary genistein, with proven anticancer activity, would improve bacteriophage 
anticancer safe therapy. We show that combination treatment with genistein and 
AAVP increased targeted cancer cell killing by AAVP carrying the gene for Herpes 
simplex virus thymidine kinase (HSVtk) in 2D tissue cultures and 3D tumor spheroids. 
We found this increased tumor cell killing was associated with enhanced AAVP-
mediated gene expression. Next, we established that genistein protects AAVP against 
proteasome degradation and enhances vector genome accumulation in the nucleus. 
Combination of genistein and phage-guided virotherapy is a safe and promising 
strategy that should be considered in anticancer therapy with AAVP. 
INTRODUCTION
Cancer is a major cause of mortality and morbidity 
worldwide despite progress in the conventional 
therapies and despite the fact that several mechanisms 
of oncogenesis are now understood. Developing efficient 
systemic therapies would play a major advance in cancer 
treatment. Indeed, most cancer patients die of metastases 
and systemic chemotherapy is the most widely used 
treatment for cancer. The major obstacle to the success 
of chemotherapy in cancer treatment is the development 
of tumor drug resistance. In addition, chemotherapy 
is not specific and the dose of the drug that reaches the 
tumor may be as little as 5%–10% of the total dose as it 
accumulates in normal organs [1].
Cancer gene therapy is a promising approach for 
cancer treatment. Gene therapy was initially conceived as 
a treatment for inherited diseases, but today up to 70% of 
clinical trials of gene therapy are designed to treat cancer. 
Gene therapy uses carriers called vectors to deliver the 
therapeutic gene to the patient’s target cells. Currently, 
the most common vectors are eukaryotic viruses because 
they can enter cells as part of the natural infection 
process. Eukaryotic viruses are, unquestionably, superior 
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vectors for gene transfer, but have had limited success in 
systemic gene therapy as they are taken up by the liver 
and reticulo-endothelial system, they have broad tropism 
for healthy tissues and they may lose efficacy due to the 
presence of neutralising antibodies [2]. A local vector 
delivery through intra-tumoral injection can be used to 
show proof of efficacy, but in practice clinical benefit for 
cancer treatment can only be achieved following systemic 
administration.
In 2006, we were the first to describe a novel 
systemic gene therapy vector based on bacteriophage 
(phage) that showed successful targeting of gene delivery 
to tumors in preclinical models of cancer following 
intravenous administration. We named this vector adeno-
associated virus/phage or AAV/phage (AAVP) [3]. One 
advantage of using phage vectors over animal viral 
vectors is that bacteriophage has a safety history profile 
as it was given to humans to treat bacterial infections, 
and was approved in 2006 by the US Food and Drug 
Administration for use as safe antibacterial food additive 
[4]. Other advantages of phage vectors are their large 
cloning capacity as well as their simple and economical 
large-scale production and purification [5]. Finally, 
phage vectors are easily targetable through tissue specific 
ligands displayed on their capsid, without the need to 
ablate any native mammalian tropism. Phage display 
technology has largely shown that ligands displayed on 
the phage coat proteins remain intact and preserve their 
receptor binding properties [6]. Bacteriophage can infect 
and express genes in bacteria only. Thus the mammalian 
transgene cassette flanked by full length inverted terminal 
repeats (ITRs) from the recombinant adeno-associated 
virus (rAAV), which is mammalian single-stranded DNA 
virus, was genetically incorporated into the phage single-
stranded genome [7]. This hybrid vector (AAVP) has 
no AAV capsid but phage capsid served to package the 
hybrid single-stranded genome. As phage has no tropism 
for mammalian cells, the gene encoding the pIII minor 
coat protein of the phage was genetically manipulated to 
display, as a fusion, the cyclic CDCRGDCFC (RGD4C) 
ligand that allows targeting of the phage capsid to tumors 
through binding to its αv integrin receptors which are 
specifically expressed on tumors but barely detectable 
on the healthy tissues. Consequently, the tumor-targeted 
RGD4C-AAVP achieved specific gene expression within 
tumors after intravenous administration resulting in 
strong antitumor effects in rodents, without harming the 
healthy tissues [3, 7, 8]. Remarkably, a study carried 
out by the National Cancer Institute, NCI-USA, with 
targeted RGD4C-AAVP-TNFα carrying the gene for the 
cytokine tumor necrosis factor alpha (TNFα), showed 
specific delivery of TNFα in natural tumors in pet dogs, 
resulting in eradication of aggressive and sizeable 
tumors such as fibrosarcoma in a few cases [9]. In brief, 
RGD4C-AAVP is a novel and promising systemic vector 
for cancer treatment. 
However, while some preclinical studies showed 
remarkable outcomes, vector performance was also poor 
in some cases. One reason could be associated with poor 
intracellular trafficking of the vector as RGD4C-AAVP is 
still a bacteria virus that has not evolved to deliver genes 
to mammalian cells. We have previously investigated 
the intracellular trafficking of RGD4C-AAVP in cancer 
cells and uncovered barriers to gene delivery by RGD4C-
AAVP, such as weak phage attachment to the cell 
surface [10], poor endosomal escape [11], proteasome 
degradation [12] and nuclear transport (unpublished 
data). Proteasome inhibiting drugs and endosmolytic 
agents could be used to assist the phage to overcome 
intracellular barriers and subsequently enhance gene 
delivery. However, these drugs are not usually clinically 
applicable and have to be used at toxic pharmacological 
doses in order to be efficient. Anticancer treatment 
strategies such as conventional chemotherapy have 
been used to enhance gene therapy [13] and can be 
tested in combination with RGD4C-AAVP. However, 
chemotherapy is an invasive and toxic treatment with 
ferocious chemistry unable to differentiate between 
cancerous and healthy cells [1]. Herein, we postulated 
that the natural non-toxic dietary plant product, 
genistein, with proven anticancer activity can be used to 
enhance the RGD4C-AAVP-mediated tumor cell killing 
while preserving its safety attribute. Genistein is an 
isoflavone present in soy [14], that inhibits the growth 
and development of several malignancies [15–17]. 
Epidemiological studies have shown that a soy-rich 
diet is associated with low risk of breast and prostate 
cancer [18]. Genistein has already been used in clinical 
trials to investigate combined therapy of genistein and 
gemcitabine for the treatment of breast cancer patients 
and to evaluate genistein together with gemcitabine and 
erlotinib for the treatment of pancreatic cancer patients 
[19, 20]. Genistein has similar structure to 17β-estradiol 
presenting weak estrogenic activity and can compete 
with 17β-estradiol for the estrogen receptor (ER), thus 
contributing to the treatment of hormone-related cancers 
[18]. Other mechanisms mediating the anticancer effect 
of genistein include the inhibition of mitogen activated 
protein kinase (MAPK) activation resulting in sensitizing 
human hepatocellular carcinoma Hep3B cells to TNF-
related apoptosis inducing ligand TRAIL-mediated 
apoptosis [21] and also induction of apoptosis in primary 
gastric cells by downregulating the antiapoptotic 
protein B cell lymphoma2 (Bcl-2) and upregulating 
the proapoptotic Bcl-2 associated X protein (Bax) [22]. 
Genistein also targets caspases, extracellular signal-
regulated kinases 1/2 (ERK1/2), nuclear transcription 
factor κB (NF-κB), Wingless and integration 1 β-catenin 
(Wnt/β-catenin), phosphoinositide 3 kinase/Akt (PI3K/
Akt) and epidermal growth factor receptor protein 
tyrosine kinase (EGFR-PTK) signalling pathways 
resulting in anticancer and therapeutic effects [15].
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Furthermore, genistein was shown to increase AAV2-
mediated transduction efficiency [23, 24]. Importantly, 
genistein can interfere with cellular pathways and, as a 
result, can be used to enhance the gene transfer efficacy 
of RGD4C-AAVP. For instance, the ability of genistein 
to inhibit the chymotrypsin-like activity of proteasome 
[25], can be used to prevent AAVP degradation by the 
proteasome. Moreover, the ability of genistein to induce 
G2/M cell cycle arrest could result in increased nuclear 
transport of gene therapy vectors [26–28]. Consequently, 
taking into account the safety of genistein, its anticancer 
activity and interference with cellular pathways, we 
hypothesized that combination of genistein with our 
tumor-targeted RGD4C-AAVP biotherapeutic particle 
would lead to enhanced tumor cell killing along with 
reduced toxicity. We also examined the effects of 
genistein on targeted gene transfer by RGD4C-AAVP 
in vitro and in tumor spheroid models, and investigated 
the mechanism of genistein’s effects on RGD4AC-AAVP.
RESULTS
Genistein drug treatment boosts cancer cell 
death by phage-mediated suicide gene killing 
First, we sought to assess the cytotoxicity of genistein 
in vitro on 9L rat glioblastoma and M21 human melanoma 
cell lines. These tumor cells were treated with increasing 
concentrations of genistein ranging from 50 to 3300 μM for 
2 hours and compared to non-treated cells. Subsequently, 
cell survival was assessed at 48 hours post drug treatment. 
The data show that tumor cell death raised as the 
concentration of the drug increased (Figure 1) in both 9L 
and M21 cancer cells with a more pronounced effect on the 
9L glioblastoma cells than M21 melanoma cells. Cytotoxic 
doses expressed as IC50 values, showing the inhibitory 
concentrations required to induce the cell death by 50%, 
are shown in Table 1. We found that 50% of cell death in 
the presence of genistein was induced by ~438.5 μM in 
9Lcells (Table 1), while in M21 cells, 50% of cell death 
was achieved at a dose of over 1148 μM (Table 1). Next, 
to assess the effect on tumor cell killing by RGD4C-AAVP, 
we selected genistein concentration of 150 μM for both 9L 
and M21 cancer cells, as this dose is below the IC50, causes 
little toxicity and was previously reported to enhance gene 
delivery by eukaryotic viral vectors [24]. 
To test tumor cell killing efficacy, we used the 
RGD4C-AAVP vector (RGD-HSVtk) encoding the gene 
for the herpes simplex virus type I thymidine kinase 
(HSVtk) mutant SR39 [29] which kills cells in the 
presence of ganciclovir, GCV (Figure 2). 9L and M21 
cells were transduced with RGD-HSVtk or control non-
targeted vector fd-HSVtk (without RGD4C) carrying the 
HSVtk gene with or without 2 hours pretreatment with 
genistein. The cells were then treated with GCV (20 μM) 
at day 3 post vector transduction. Cancer cell killing was 
quantified at 0, 24, 48, 72, 96 hours post GCV treatment. 
Results were normalized to non-targeted vector which did 
not show any tumor cell death (data not shown). In both 
cancer cell lines, the combination treatment with genistein 
and RGD-HSVtk therapy resulted in greater cell killing 
compared to cells treated with RGD-HSVtk or genistein 
drug alone (Figure 2). For instance, at 72 hrs post GCV 
treatment, combination treatment induced 91.6% and 
70.5% killing of 9L and M21 cancer cells, respectively 
(Figure 2), compared to 79.5% and 44.7% death induced 
by RGD-HSVtk vector alone in 9L and M21 cells, 
respectively, and 69.8% death and 49.6% death induced 
by genistein alone in 9L and M21 cells, respectively. 
These data show that drug treatment of cancer cells with 
an isoflavone is a promising approach to enhance targeted 
gene therapy by RGD4C-AAVP.
Genistein increases targeted reporter gene 
transfer by the RGD4C-AAVP in 9L and M21 
cancer cells in vitro
To gain insight into the improved tumor cell killing 
by RGD-HSVtk following combination with genistein, we 
investigated the effect of genistein on gene delivery by 
RGD4C-AAVP. We first conducted qualitative analyses 
of transgene expression by using vectors carrying the 
reporter gene of the green fluorescent protein (RGD-GFP) 
and combined with 2 hours pretreatment with 150 μΜ of 
genistein (Figure 3). Fluorescent microscopic analysis of 
GFP expression at day 4 post vector transduction showed 
that combination treatment with RGD-GFP and genistein 
resulted in significantly higher GFP expression, compared 
to RGD-GFP vector alone in both 9L and M21 tumor 
cells (Figure 3A–3D). Next, to confirm the increased gene 
delivery by RGD4C-AAVP in combination with genistein, 
we carried out a quantitative analysis of transgene 
expression over a time course of 4 days post vector 
transduction by using RGD4C-AAVP vectors expressing 
the firefly luciferase reporter gene, RGD-Luc, (Figure 3E 
and 3F). Consistently with GFP reporter transgene 
expression experiments, we observed a significant 
increase in luciferase expression by RGD-Luc vector at 
various time points post vector transduction by genistein 
treatment in both 9L and M21 cancer cells compared to 
cells treated with the vector alone. For instance at day 4 
post transduction, combination treatment (RGD-Luc + 
Genistein) resulted in ~ 4.7 fold and ~3.8 fold increase in 
luciferase expression in 9L and M21 cells, respectively, 
compared to RGD-Luc treatment alone. Moreover, in 9L 
cells, initiation of the luciferase expression occurred as 
early as day 2 post vector transduction, in the presence 
of genistein (Figure 3E). Importantly, no luciferase 
expression was detected in cells transduced with non-
targeted fd-Luc vector alone or in combination with 
genistein, which shows that genistein does not affect the 
specificity and targeting of the RGD4C-AAVP vector.
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Finally, we sought to investigate whether this 
enhanced AAVP gene delivery by genistein could also 
occur with other dietary phytochemicals. In this study 
we selected the phytochemicals curcumin and EGCG 
(epigallocatechin-3-gallate) known for their anticancer 
properties. First, we assessed the cytotoxicity of curcumin 
and EGCG on both 9L and M21 cells and determined the 
IC50 (Supplementary Figures 1 and 2, Table 1). Next, we 
used non-toxic doses of curcumin and EGCG below the 
IC50 (Table 1), and evaluated 9L and M21 cell transduction 
Figure 1: Cytotoxicity of genistein on 9L and M21 tumor cells. 9L (A) and M21 (B) cells were cultured in 96-well plates, then 
treated with increasing concentrations of genistein ranging from 50 to 3300 μM for 2 hours. Next, cells were grown for further 48 hours 
without the drug. Cell survival was determined by using the MTT assay and expressed as percentage of cells counted in parallel cultures 
without the drug. The IC50 dose of genistein determined by GraphPad Prism using nonlinear regression was 438.5 μM for 9L cells and 1148 
μM for M21 cells. The X-axis is in the log(10) scale and the data fitted to Hill equation. The assay was repeated twice in triplicate and the 
results shown are representative of one experiment.
Figure 2: Genistein increased cell death of 9L and M21 tumor cells after transduction with RGD-HSVtk followed by 
GCV treatment. 9L (Α) and M21 cells (B) grown in 48 well-plates (60–80% confluent) were transduced with RGD-HSVtk targeted 
vector or control non-targeted fd-HSVtk vector with or without 2 hours pretreatment with genisteιn (150 μΜ). The cells were treated with 
GCV (20 μM) at day 3 post vector transduction and renewed daily. Cancer cell killing was quantified at 0, 24, 48, 72, 96 hours post GCV 
treatment. Cells were counted by using the trypan blue exclusion methodology. Results are normalized to control non-targeted fd-HSVtk 
vector. The experiment was repeated twice in triplicate and the results shown are representative of one experiment.
Table 1: IC50 of genistein, curcumin, EGCG, bortezomib and carfilzomib in 9L and M21 cells
9L cells M21 cells
Cytotoxic agent Genistein Curcumin EGCG Bortezomib Carfilzomib Genistein Curcumin EGCG Bortezomib Carfilzomib 
IC50 (µM) 438.5 35.05 203.7 1.55 1.034 1148 42.38 361.9 1 1.141
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by RGD-Luc in combination with curcumin and EGCG. 
We found that curcumin increased the transduction 
efficiency of the targeted RGD-Luc in 9L cells, in a dose 
dependent manner (Supplementary Figure 1C), but not in 
the M21 cells (Supplementary Figure 1D). Importantly, 
no effect of curcumin was observed on the control non-
targeted fd-Luc vector proving that curcumin did not affect 
the specificity of the targeted RGD-Luc vector. Finally 
treatment with EGCG did not increase the transduction 
efficiency of the RGD-Luc vector in both cell lines 
(Supplementary Figure 2).
Evaluation of vector cellular entry following 
genistein pretreatment
After demonstrating that the increased tumor cell 
killing by RGD4C-AAVP observed in combination with 
genistein was associated with enhanced RGD4C-AAVP-
mediated gene expression, we set out to gain further 
understanding into the mechanism of this enhanced 
gene transfer. Therefore, we sought to investigate the 
effect of genistein on steps involved in gene transfer. It 
is well established that vector-mediated gene delivery 
depends on several steps where the vector needs to 
access the cell surface to bind to its receptor, followed 
by cell internalization and intracellular trafficking, then 
transport to the nucleus for gene expression to occur 
[30, 31]. We first examined the effect of genistein 
on vector attachment to the surface of cells, as we 
previously reported that gene transfer by RGD4C-AAVP 
is hindered by its weak accessibility to the surface of 
tumor cells [10]. Hence, we quantified the free cell-
unbound phage in the supernatant above the adherent 
cells by infection of host bacteria followed by colony 
counting (Figure 4A). An amount of 52%, of input 
phage particles, was recovered from the supernatant of 
cells treated with the RGD-GFP vector showing that a 
fraction of 48% of input phage was bound to the surface 
of tumor cells. However, pretreatment with genistein 
had no effect on vector attachment to the cell surface 
(Figure 4A). The non-targeted fd-GFP vector showed 
no attachment to the surface of tumor cells with 100% 
recovery. Finally, internalization assays revealed that 
combination of vector with genistein did not increase 
entry of the RGD4C-AAVP into cancer cells (Figure 4B 
and 4C). These data show that genistein has no effect on 
Figure 3: Genistein increased efficiency of gene transfer by AAVP in 9L and M21 tumor cells. 9L (A) and M21 cells 
(B) were plated on 48-well plates (70–80% confluent) and transduced with RGD-GFP targeted  or control non-targeted vectors in serum 
free medium for 4 hours with or without 2 hour pretreatment with genistein (150 μΜ). GFP expression was monitored by fluorescent 
microscopy on day 4 post vector transduction, and also evaluated as average of GFP positive cells in five fields of view of 9L (C) and M21 
(D) treated cells. 9L (E) and M21 cells (F) were plated on 48-well plates (70–80% confluent) and transduced with targeted RGD-Luc or fd-
Luc control non-targeted vector in serum free medium for 4 hours with or without 2 hours pretreatment with genistein (150 μΜ). Luciferase 
measurement assays were performed at day 1–4 post vector transduction and normalized to protein concentration as determined by the 
Bradford assay. Results are shown as RLU (Relative Luciferase Units) per 1 μg of protein and represent the average from triplicate wells. 
The experiment was repeated twice in triplicate and the results shown are representative of one experiment.
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cell attachment and internalization of the RGD4C-AAVP 
viral particles.
Genistein protects RGD4C-AAVP from 
proteasome degradation
After ruling out the effect of genistein on vector cell 
entry, we sought to determine whether genistein improves 
intracellular persistence of the RGD4C-AAVP. We 
investigated the effect of genistein pretreatment of tumor 
cells on vector protection against proteasome degradation 
as we previously reported that proteasome is a barrier to 
gene transfer by RGD4C-AAVP vectors [12], and because 
genistein was found to possess proteasome-inhibitory 
activity [25]. 26S proteasome targets the degradation 
of polyubiquitinated protein substrates; thus inhibition 
of proteasome degradation by genistein would lead to 
accumulation of AAVP ubiquitination [32]. Therefore, we 
investigated whether genistein increases polyubiquitination 
of AAVP phage coat proteins. 9L tumor cells were transduced 
with RGD-Luc vector alone or following pretreatment with 
genistein. Next, the cells were analyzed for co-localization 
of AAVP coat proteins and ubiquitin by immunofluorescence 
as reported [33], by using antibodies against ubiquitin and 
phage coat proteins (Figure 5). Confocal microscopic 
analysis showed strong co-localization of ubiquitin and 
AAVP coat proteins in cells treated with combination of 
vector and genistein (Figure 5). These data demonstrate 
that combination treatment results in accumulation of 
polyubiquitinated AAVP particles compared to treatment 
with the targeted vector alone, indicating that genistein 
can increase the gene transfer efficiency by inhibiting 
proteasome-mediated degradation of AAVP particles. 
Genistein enhances nuclear localisation of the 
RGD4C-AAVP vector genome
Finally, we examined vector’s genome accumulation 
in the nucleus to check whether enhanced resistance 
of vector to proteasome degradation would result in 
enhanced nuclear localisation of vector’s genome. 
Additionally, genistein has been reported to induce G2/M 
cell cycle arrest, which results in pronounced opening 
of the nuclear pores allowing better nuclear transport of 
gene delivery vectors [26–28].Thus, we evaluated the 
nuclear accumulation of the AAV2 transgene cassette, 
since gene expression by RGD4C-AAVP is mediated 
through its AAV2 transgene cassette. 9L cells were 
Figure 4: Analysis of cellular attachment and internalization of AAVP vector in combination with genistein. (A) Cellular 
attachment of RGD4C-GFP was evaluated by titrating the unbound phage in the supernatant of 9L cells following bacterial colony counting. 
The experiment was repeated twice in triplicate and the results shown are representative of one experiment. (B) Evaluation of vector 
internalization in the presence or absence of genistein. Graph showing FACS results after immunostaining of 9L cells treated with vectors 
in the presence or absence of genistein. (C) Graph showing the percentage of positive cells according to FACS data at three different time 
points (1, 2 and 4 hours) post incubation with vector. The experiment was carried out in triplicate.
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transduced with RGD-Luc or fd-Luc non-targeted vector 
with or without 2 hours pretreatment with genistein 
(150 μΜ), and harvested at day 4 post transduction. Next, 
the nuclei were extracted from cells, followed by PCR 
using primers reading within the AAV2 ITR domain, as 
previously described [34], in order to semi-quantify the 
amount of vector genome in the nucleus (Figure 6). The 
data revealed a PCR product at the expected size, and 
electrophoresis gel analysis showed increased intensity 
of the ITR-derived PCR product when RGD-Luc vector 
was used in combination with genistein (Figure 6A). Then 
product quantification of the band intensities using ImageJ 
software confirmed that combination of genistein with the 
targeted vector resulted in significant increase of vector 
DNA in the nucleus (Figure 6B). 
Evaluation of efficacy of genistein and RGD4C-
AAVP combination in a three-dimensional (3D) 
multicellular tumor spheroid
After showing that genistein dramatically increased 
RGD4C-AAVP mediated targeted killing of tumor cells 
in vitro, we set up to assess the efficacy of this 
combination in 3D tumor spheroids that simulate the 
Figure 5: Polyubiquitination of RGD4C-AAVP particle is increased by genistein. (A) 9L cells were transduced by targeted 
AAVP (RGD-Luc) in serum-free medium for 4 hours with or without pretreatment with genistein (150 μM). 6 hours post transduction, 
RGD-Luc was detected using rabbit anti-M13-phage primary and goat anti-rabbit AlexaFluor-647 secondary antibodies (shown in red) 
and ubiquitin was stained using mouse anti-ubiquitin primary and AlexaFluor-488 secondary antibodies (shown in green). Samples were 
analyzed by confocal microscopy and representative sections are shown. (B) Corrective total cell fluorescence analysis of ubiquitination 
in single optical sections using ImageJ. Data represent the mean ± standard error of the mean (s.e.m.) of five independent optical sections.
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3D tumors more accurately. The 3D tumor spheroids are 
considered valid models to recapitulate features of solid 
tumors and were used in this study to evaluate and confirm 
the efficacy of gene therapy by the targeted RGD4C-
AAVP in combination with genistein. Since the increased 
tumor cell killing in vitro of the combination genistein and 
RGD4C-AAVP was associated with the enhancing effect 
of genistein on RGD4C-AAVP-mediated gene transfer, 
we first assessed the efficacy of gene transfer using vector 
carrying the GFP reporter gene to allow microscopic 
imaging of GFP expression within the 3D models of 9L 
and M21 tumor spheroids (Figure 7). The 9L and M21 
tumor spheroids were transduced with targeted RGD-
GFP or control non-targeted fd-GFP with or without 
pretreatment with genistein (150 μΜ). GFP expression 
was monitored with fluorescent microscopy over a period 
of 10 days to allow detectable gene expression by the 
RGD-GFP in the spheroids. While the targeted RGD-GFP 
showed minimal GFP expression in the spheroids at day 
10 post transduction, combination treatment (RGD-GFP 
+ Genistein) yielded dramatic increase in GFP expression 
compared to RGD-GFP treatment alone in both 9L and 
M21 spheroids (Figure 7).
Next, application of HSVtk/GCV suicide gene 
therapy on rat 9L and human M21 tumors in vitro resulted 
in regression of the 9L and M21 spheroid volumes by 
combination of genistein with the targeted RGD-HSVtk 
upon GCV treatment, compared to individual treatments 
with RGD-HSVtk or genistein alone (Figure 8A and 8B). 
Subsequently, measurement of cell viability in 9L 
spheroids showed that combination of genistein plus RGD-
HSVtk achieved higher tumor cell killing ~93%, than the 
targeted RGD-HSVtk or genistein alone that induced ~81% 
and ~33% cancer cell killing, respectively (Figure 8C). In 
M21 spheroids, measurement of cell viability showed that 
combination of genistein plus RGD4C-HSVtk achieved 
higher tumor cell killing ~65% than the targeted RGD-
HSVtk or genistein alone that induced ~33% and ~24% 
cancer cell killing, respectively (Figure 8D). These 
findings clearly establish that combination of genistein 
with RGD4C-AAVP-mediated gene therapy greatly 
increases its potential as a gene therapy vector.
DISCUSSION
We have demonstrated that genistein pretreatment 
of tumor cells from different histopathological types and 
species resulted in enhanced targeted tumor cell killing 
by RGD4C-AAVP-mediated HSVtk and GCV suicide 
gene therapy in 2D tissue culture and 3D tumor spheroid 
settings. Then, we found that treatment with genistein of 
9L and M21 cancer cells increased GFP and Luc reporter 
gene expression, which demonstrates that the enhanced 
tumor cell killing of RGD4C-AAVP by genistein is 
associated with increased HSVtk gene expression. 
Moreover, we have investigated the mechanisms linked 
with this increased reporter gene expression and tumor 
cell killing. Importantly gene transfer by RGD4C-AAVP 
remains targeted in the presence of genistein, indicating 
that the tumor specificity of RGD4C-AAVP is not affected 
Figure 6: Genistein enhances AAVP vector genome accumulation in the nucleus. (A) 9L cells  were plated on 48-well plates 
(70–80% confluent) and transduced with targeted RGD-Luc or fd-Luc control non-targeted vector in serum free medium for 4 hours with or 
without 2 hours pretreatment with genistein (150 μΜ). On day 4 after transduction, cells were harvested and nuclei extracted. Subsequently, 
DNA was extracted and used as template (10 ng of DNA) for PCR of the ITR domain in order to semi-quantify the amount of vector in the 
nucleus with or without pretreatment with genistein. Similar amount of DNA (10 ng) was used as template for PCR of the GAPDH gene. 
The experiment was carried out in triplicate. (B) The band intensity of the ITR PCR product was quantified using ImageJ software and 
normalized to GAPDH. PCR of the ITR domain was repeated three times and shown is the average.
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by genistein. We also found that genistein increases 
polyubiquitination of AAVP particles and accumulation 
of vector genome in the nucleus. These data suggest that 
genistein may bestow an advantage in gene expression 
from RGD4C-AAVP by means of increased vector 
accumulation in the nucleus and vector protection from 
proteasome degradation, or perhaps a combination of these 
two non-mutually exclusive mechanisms. 
Our findings of increased RGD4C-AAVP-mediated 
cancer gene therapy are in agreement with a previous 
report showing enhanced cancer cell killing by a mutant 
oncolytic adenovirus in combination with genistein [35]. 
The observed difference in cell viability between 9L and 
M21 cell lines can be attributed partially to the fact that 
9L cells can get transduced more easily compared to M21 
cells and also to the bystander effect of the HSVtk/GCV 
in 9L cells [36]. The enhanced RGD4C-AAVP-mediated 
GFP and Luc gene expression by genistein is also 
consistent with previous reports that genistein increased 
AAV2-mediated gene transfer in the human HeLa cervical 
carcinoma cells [23]. Moreover, the authors reported that 
genistein enhanced accumulation of the dephosphorylated 
form of single-stranded D-sequence-binding protein (ssD-
BP), which facilitates the conversion of single to double 
stranded DNA resulting in improved AAV gene expression 
[23]. Importantly, our findings that genistein increased 
AAV2 PCR product in the nuclear fraction of cells treated 
with RGD4C-AAVP are consistent with that study, as gene 
expression by RGD4C-AAVP is mediated by the AAV2 
transgene cassette, incorporated within the phage genome. 
The increased nuclear accumulation of AAVP genome, 
upon genistein pre-treatment, provides an additional 
mechanism that could further explain the improved AAVP-
mediated gene expression by genistein. One explanation is 
that pretreatment with genistein enhances the size of the 
nuclear pores, as genistein was reported to induce G2/M 
cell cycle arrest, during which nuclear localisation of gene 
therapy vectors can be enhanced [26–28]. 
Moreover, resistance to proteasome degradation 
upon genistein pretreatment should result in better 
intracellular persistence and availability of the RGD4C-
AAVP particles to be transported to the nucleus. These 
data also suggest that genistein increases the RGD4C-
AAVP-targeted gene expression, at least in part, through 
inhibition of proteasome-mediated degradation of the 
RGD4C-AAVP particles. Indeed, genistein was reported 
to inhibit the chymotrypsin-like activity of proteasome in 
purified 20S proteasome and 26S proteasome [25]. Also, 
Figure 7: Genistein increased RGD4C-AAVP-mediated gene transfer in 9L and M21 tumor spheroids. 9L (A) and M21 
(B) cells (5 × 103) were seeded into a 96-well ultra-low attachment surface plate in 200 μL complete medium. After 48 hours of incubation, 
a spheroid was formed in each well. Spheroids were then transduced with RGD-GFP or control fd-GFP non-targeted vector with or without 
pretreatment with genistein (150 μΜ). GFP expression was evaluated with fluorescent microscopy at day 10 post vector transduction.
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this is in agreement with our previous report showing that 
the proteasome inhibitors MG132 and LLnL increased 
persistence of RGD4C-AAVP particles in cancer cells 
in vitro and in tumors in vivo and subsequently improved 
gene expression from the vector both in vitro and in vivo 
[12]. MG132 and LLnL are peptide aldehyde inhibitors 
that reversibly inhibit the 26S proteasome activity and 
most widely used in proteasome inhibition studies. 
The clinically used proteasome inhibitors bortezomib 
and carfilzomib, in patients with myeloma and other 
haematological malignancies, were reported to increase 
transduction efficiency of AAV vectors in hepatic cells 
and HeLa cell line [37, 38]. However, bortezomib and 
carfilzomib did not show any enhancing effect on the 
transduction efficiency of RGD4C-AAVP in 9L and 
M21 cancer cell lines, although using various doses 
(Supplementary Figures 3 and 4). Compared to MG132 
and LLnL, bortezomib and carfilzomib are stronger 
proteasome inhibitors even when used at low doses, 
which could result in increased cancer cell distress and 
subsequent reduction of RGD4C-AAVP gene expression.
Taking into account that genistein doesn’t affect 
vector attachment on the surface of cancer cells nor its 
internalisation (Figure 4), our data indicate that genistein 
affects the intracellular fate of AAVP. It is important to note 
that other mechanisms of action of genistein might also 
Figure 8: Antitumor efficacy of RGD4C-AAVP in combination with genistein in 3D tumor spheroid models. Bright-field 
images showing the size of 9L (Α) and M21 (B) spheroids following transduction with RGD-HSVtk or fd-HSVtk non-targeted vector with 
or without  pretreatment with genistein (150 μΜ). GCV was added to the spheroids at day 5 post vector transduction and renewed every 
2 days. Images were taken at day 5 or day 7 post GCV treatment for 9L and M21 spheroids, respectively. (C) Evaluation of cell viability 
in 9L spheroids at day 5 post GCV treatment. (D) Evaluation of cell viability in M21 spheroids at day 7 post GCV treatment. Cell viability 
was assessed by using the Cell Titer-Glo cell viability assay. The experiments were repeated twice in triplicate and the results shown are 
representative of one experiment.
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account for its enhancing effect on transduction efficiency 
of RGD4C-AAVP. For instance, genistein was reported 
to modulate the lysosomal metabolism [39]. Given that 
the endosomal-lysosomal pathway has been identified 
as an intracellular barrier to efficient transduction by 
RGD4C-AAVP [11], lysosomal alteration by genistein 
might facilitate RGD4C-AAVP escape from the lysosomes 
and subsequently higher nuclear accumulation of AAVP 
genome and enhanced gene expression.
In conclusion, despite their advantageous natural 
characteristics, bacteriophage viruses are still considered 
poor vectors for gene delivery due to their low gene 
transfer efficiency compared to eukaryotic vectors. The 
AAVP vector was reported as an improved version of 
phage-based gene therapy vectors to achieve enhanced 
gene delivery compared to conventional phage-derived 
vectors. Although promising, AAVP still has limitations 
inherent to bacteriophage. In this study we have shown 
that combining targeted RGD4C-AAVP with genistein 
significantly improves AVVP-guided gene transfer efficacy 
and consequently its cancer cell killing as a gene therapy 
vector. In addition, we elucidated possible mechanisms of 
increased AAVP-mediated gene expression by genistein. 
The next preclinical step will be taken to assess efficacy 
of this combination treatment in tumor-bearing mice. 
Given that genistein and AAVP have been demonstrated 
to cross the blood-brain barrier [40, 41], this combination 
treatment has potential applications for brain tumors. Our 
study indicates that combination of RGD4C-AAVP and 
genistein, is a promising strategy that can be considered 
for future clinical applications of targeted systemic gene 
therapy with RGD4C-AAVP in cancer patients.
MATERIALS AND METHODS
Cells and reagents
The rat 9L glioblastoma cells were a gift from Dr 
Hrvoje Miletic (University of Bergen, Norway), while the 
human M21 melanoma cells were from the American Type 
Culture Collection (ATCC). Both cell lines were maintained 
in a humidified incubator at 37oC in 5% CO2 and cultured 
in Dulbecco’s Modified Eagle’s Medium (Sigma) 
supplemented 10% fetal bovine serum (FBS, Sigma), 
penicillin (100 units/ml, Sigma), streptomycin (100 μg/ml, 
Sigma), and L-glutamine (2 mmol/l, Sigma). Genistein was 
purchased from Sigma and a stock solution (150 mM) was 
prepared in dimethyl sulfoxide (DMSO, Sigma).
MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide] assay
Cytotoxicity of genistein was assessed by using the 
MTT assay (colorimetric assay to measure cell viability 
based on mitochondrial activity, Sigma). 9L and M21 cells 
were plated in 96-well plates at a density of 4 x 103 cells 
per well. Next day, complete medium (100 μl) containing 
different concentrations of genistein were added to cells 
in triplicates. After 2 hours treatment, the genistein-
containing medium was removed and replaced with 100 μl 
fresh medium. MTT assay was carried out after 48 hours.
Production, purification and titration of AAVP 
vectors
AAVP vectors were generated as previously 
reported [7] by inserting the mammalian cassette from 
AAV2 containing the reporter or therapeutic genes into 
the fUSE5 plasmid derived from the filamentous fd-tet 
bacteriophage. AAVP viral particles were produced and 
purified from the culture supernatant of Escherichia Coli 
K91 host bacteria as previously described [7], then sterile-
filtered through 0.45 μM filters. The titration was carried 
out by preparing serial dilutions of the AAVP and infecting 
K91 host bacteria, which subsequently form colonies when 
plated on selective Luria-Bertani agar. The AAVP titre is 
calculated by counting the number of colonies multiplied 
by the dilution of the AAVP and is expressed as bacterial 
transducing units (TU/μl) as previously described [7].
In vitro cell transduction by AAVP vectors
9L and M21 cells were counted, then plated on 
48-well plates and grown for 48 hours until they reach 
70–80% confluence. Genistein was diluted in complete 
medium and added to the cells (as indicated) at a final 
concentration of 150 μM [24].  After 2 hours treatment, 
genistein-containing medium was removed and cells were 
washed with serum-free medium. Subsequently, cells were 
incubated with targeted RGD4C-AAVP or control non-
targeted AAVP vectors (106 TU/cell for HSVtk carrying 
vectors, 2.5 × 105 TU/cell for GFP carrying vectors, 
and 104 TU/cell for Luc carrying vectors) in serum-free 
medium (150 μl total volume per well) at 37oC in the CO2 
incubator for 4 hours and manually rotated every 30 min 
during incubation. After 4 hours, 350 μl of complete 
medium were added to make the total volume up to 500 μl 
per well.  Cell transduction efficacy in vitro was evaluated 
by using the green fluorescent protein (GFP) and the 
firefly luciferase (Luc) reporter genes. The variation in the 
TU/cell amounts used between vectors carrying different 
transgenes is related to the sensitivity of the assay. For 
instance, given the sensitivity of the luciferase assay, we 
used 104 TU/cell to avoid saturation of the signal.
Reporter gene assays
Quantification of luciferase expression was carried 
out by using the Steady-Glo luciferase assay (Promega). 
Medium was removed and 110 μl of Glo Lysis buffer, was 
added per well of 48 well plate. After 10 min incubation, 
50 μl of the cell lysate was transferred to a 96-well white 
opaque microplate (BD, Falcon) and mixed with an equal 
volume of Steady-Glo® luciferase substrate (Promega). 
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After 10 min the plate was read using a Promega Glomax 
plate reader. Luciferase expression was normalized to 
100 μg protein levels from cell lysates as determined 
by the Bradford assay (Sigma). Results are shown as 
Relative Luciferase Units (RLU) per 100 μg of protein. 
GFP expression was visualized using a Nikon Eclipse 
TE2000-U fluorescence microscope.
Determination of tumor cell killing in vitro
9L and M21 cells were seeded in 48 well-plates 
for 48 hours until they reach 70–80% confluence. Then, 
cells were transduced with RGD4C-AAVP or control non-
targeted vector carrying thymidine kinase of the herpes 
simplex virus type 1 (RGD-HSVtk) gene with or without 
2 hours pretreatment with genistein (150 μΜ). Ganciclovir 
(GCV, Sigma) was added to the cells (20 µM) at day 3 
post vector transduction and renewed daily. Cancer cell 
killing was quantified at 0, 24, 48, 72, 96 hours post GCV 
treatment. Cells were counted by using the trypan blue 
exclusion methodology. Results were normalized to non-
targeted vector (fd-HSVtk).
3D model of multicellular tumor spheroid 
culture and treatment
9L and M21 multicellular tumor spheroids were 
prepared by seeding 5 × 103 cells into a 96-well ultra-low 
attachment surface plate (Corning) in 200 μL complete 
medium. After 48 hours of incubation, a spheroid was 
formed in each well. Then, after removing 100 μl of media, 
spheroids were incubated with targeted vectors or control 
non-targeted vectors in 100 μl complete medium with or 
without 2 hours pre-treatment with genistein (150 μΜ). 
24 hours later, the medium was replaced with 200 μl 
complete medium and renewed every 3 days by fresh 
complete medium. GFP gene expression was evaluated 
using fluorescent microscopy at day 10 post transduction. 
When spheroids were transduced with vectors carrying 
the HSVtk gene, GCV (20 μΜ) were added on day 5 
post vector transduction and renewed every 2–3 days. 
Cell viability in the spheroids was evaluated post GCV 
treatment by using CellTiter-Glo assay (Promega). First, 
medium was removed and then 100 μl of Glo Lysis buffer, 
1x, were added in each well. After 30 min incubation, the 
spheroids were dissolved by pipetting in the lysis buffer or 
using a sonicator. 50 μl of the lysate was then transferred 
to a 96-well white opaque microplate (BD Falcon), mixed 
with an equal volume of CellTiter-Glo substrate (Promega) 
and read with a Promega Glomax plate reader.
Nuclei extraction
9L cells were plated on 48-well plates (70–80% 
confluent) and transduced with RGD4C-AAVP carrying 
the Luc gene (RGD-Luc) or control non-targeted fd-Luc 
vectors in serum-free medium for 4 hours with or without 
2 hours pretreatment with genistein (150 μΜ). On day 4 
after transduction, cells were harvested and nuclei were 
extracted as previously reported [42]. Cells were washed 
with phosphate buffered saline (PBS, Sigma), trypsinized 
and then pelleted by centrifugation at 1500 × g for 5 min. 
The pellet was washed with PBS and pelleted again by 
centrifugation at 1500 × g for 5 min. Subsequently, the 
pellet was resuspended in hypotonic buffer (20 mM 
Hepes-KOH, pH 8.0, 5 mM KCl, 1.5 mM MgCl2, 5 mM 
Sodiumbutyrate, 0.1 mM dithiothreitol [DTT]) and lysed 
by dounce homogenization. Nuclei were collected by 
centrifugation (10 min, 16,000 × g, 4oC) and resuspended 
in nuclear extraction buffer (15 mM Tris-HCl, pH 7.5, 
1 mM EDTA, 0.4 M NaCl, 10% sucrose, 1 mM DTT). 
DNA was extracted using Phenol/Chloroform/Isoamyl 
alcohol mixture (Sigma) and precipitated by 100% ethanol 
(Sigma). The precipitates were washed with 80% ethanol 
and resuspended in 10 mM Tris-HCl, pH 8.5.
Semi-quantitative polymerase chain reaction 
(PCR) analysis
After extraction, DNA was used as a template for 
PCR targeting the ITR domain of the vector in order 
to semi-quantify the amount of vector in the nucleus 
with or without pretreatment with genistein.  The 
same amount of DNA was used as template for PCR 
of the GAPDH gene. PCRs were performed in a 25 μl 
volume containing 2 mM MgCl2, 0.4 mM dNTP mixture 
(Invitrogen), 0.2 μΜ forward ITR primer (fwd ITR 
primer, 5′-GGAACCCCTAGTGATGGAGTT-3′), 
0.2 μΜ reverse ITR primer (rev ITR primer, 
5′-CGGCCTCAGTGAGCGA-3′), 10 ng DNA template 
and 1 Unit of Q5 polymerase (New England Biolabs). 
The PCR program contained an initial denaturation step 
at 98oC for 10 min followed by 35 cycles of denaturation 
at 98oC for 15 sec, annealing at 61.5oC for 30 sec, and 
extension at 72oC for 1 min, with a final extension after the 
last cycle at 72oC for 5 min [34]. The 62-bp PCR product 
was analyzed on a 4% agarose gel. The band intensity of 
the PCR product was quantified using ImageJ software 
and normalized to GAPDH PCR product (Fwd gapdh 
primer: 5′-ATGAATACGGCTACAGCAACAGG-3′, Rev 
gapdh primer: 5′-CTCTTGCTCAGTGTCCTTGCTG-3′). 
Attachment assay
9L and M21 cells were seeded in 48-well plates and 
grown for 48 hours until they reach 70–80% confluence. 
Genistein was diluted in complete medium and added to 
the cells (as indicated) at a final concentration of 150 μM 
[24]. After 2 hours treatment, genistein-containing medium 
was removed and cells were treated with targeted or 
control non-targeted AAVP vectors (106 TU/cell) in serum 
free medium (150 μl total volume per well). The plates 
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were placed on ice for 1 hour to prevent internalization 
of AAVP. Next, the supernatants were collected and 
serially diluted in PBS. The amount of AAVP particles 
in the supernatant was quantified using the K91 bacterial 
infection method, as previously described [7].
Internalization assay
Internalization assay was performed as previously 
described [10]. After 2 hours treatment with medium 
containing genistein (150 μΜ), cells were incubated 
with targeted and control non-targeted vectors carrying 
the Luc gene(104 TU/cell) in serum-free medium for 1, 
2 and 4 hours at 37oC. Then, cells were cooled on ice to 
stop endocytosis and washed 3 times with PBS to remove 
unbound vectors. Cells were trypsinized for 5 min at 37°C 
(to remove surface-bound phage) and pelleted by 
centrifugation at 2000 rpm for 5 min. Subsequently, cells 
were fixed in 4% paraformaldehyde (PFA, pH 7.2, Sigma) 
for 10 minutes at room temperature. Untreated cells were 
used as negative controls. Cells were blocked with 0.1% 
saponin in 2% bovine serum albumin in PBS (BSA-PBS) 
for 30 min. To detect internalized phage-derived vectors, 
cells were stained with a polyclonal rabbit anti-M13-
bacteriophage antibody (1:1000, Sigma) in 0.1% saponin 
in 1% BSA-PBS for 1 hr at room temperature. Cells 
were washed three times (pelleted and resuspended) in 
0.1% saponin in 1% BSA-PBS. Subsequently, cells were 
incubated with the secondary antibody, goat anti-rabbit 
AlexaFluor-647 (dilution 1:500, Life Technologies) for 
1 hour at room temperature. Finally, cells were washed 
twice with 0.1% saponin-PBS and resuspended in PBS 
before analysis.
Fluorescence-activated cell sorting (FACS) analysis 
was carried out using a FACscalibur Flow cytometer 
(BD Biosciences). The mean fluorescence intensity was 
measured for at least 10,000 gated cells per triplicate 
well. Results were analyzed using Flowjo (TreeStar) 
software.
Immunofluorescence staining
9L cells were seeded on 18 mm2 coverslips in 
12-well plates. After 48 hours, cells at approximately 
80% confluent were incubated with RGD-Luc vector (106 
TU/cell) in serum-free medium with or without 2 hours 
pre-treatment with genistein (150 μM). After 4 hours, 
350 μl of complete medium were added to make up a total 
volume of 500 μl per well. After 2 hours (6 hours post 
transduction), cells were washed with PBS and fixed in 
PBS containing 4% paraformaldehyde (Sigma). Cells were 
then incubated in 50 mM Ammonium Chloride for 5 min, 
permeabilized with 0.2 % Triton X-100 (Sigma), washed, 
and blocked with PBS containing 2% BSA. Subsequently, 
cells were incubated with a rabbit anti-M13 bacteriophage 
(1:1000, Sigma) and mouse anti-ubiquitin (1:200, 
Invitrogen) diluted in 1% BSA at 4oC overnight. Next day, 
cells were washed with PBS and incubated for 1 hour at 
room temperature with 1% BSA containing anti-rabbit and 
anti-mouse Alexa Fluor-conjugated secondary antibodies 
(1:750, Invitrogen) and also DAPI (1:2000, Sigma). Cells 
were washed three times in PBS and twice in distilled 
water, allowed to air-dry and mounted in Prolong Gold 
antifade reagent (Invitrogen). Images were acquired with 
a laser confocal microscope (Leica, Germany). 
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism software (version 5.0). Data are expressed as mean ± 
standard error of the mean (s.e.m.). P values were 
generated by one-way ANOVA and Tukey tests. P values 
were considered significant when < 0.05 and denoted 
as follows: *p < 0.05, **p < 0.01, ***p < 0.001, n.s: non-
significant.
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